Expiration date: 08/2025

Indications

Essential hypertension (with the ineffectiveness of monotherapy with olmesartan or amlodipine medoxomil).

Contraindications

Hypersensitivity to olmesartan medoxomil, amlodipine and other dihydropyridine derivatives or to other components of the drug;

• liver failure of severe severity (more than 9 points on the child-Pugh scale);
  
• obstruction of the biliary tract and cholestasis;
  
• severe hypotension (GARDEN less than 90 mm Hg. V.);
  
• shock (including cardiogenic);
  
• hemodynamically unstable heart failure after myocardial infarction;
  
• renal failure of severe severity (creatinine clearance (CC) less than 20 ml/ min, no clinical experience);
  
• state after kidney transplantation (no clinical experience);
  
• conditions, accompanied by a marked violation of the outflow of blood from the left ventricle (for example, stenosis of the aorta aorta severe);
  
• pregnancy;
  
• period of breastfeeding;
  
• age up to 18 years (efficacy and safety not established);
  
• simultaneous use with aliskiren and aliskirensoderzhaschimi drugs in patients with diabetes and/or impaired renal function (glomerular filtration rate less than 60 ml/min / 1.73 m2 of body surface).
  

With caution:

• Stenosis of the aortic and mitral valve;
  
• hypertrophic obstructive cardiomyopathy;
  
• concomitant use with lithium drugs (see also section " Interaction with other drugs");
  
• hyperkalemia, hyponatremia;
  
• hypovolemia (including due to diarrhea, vomiting or simultaneous use of diuretics), as well as in patients who follow a diet with limited salt intake;
  
• renal insufficiency of mild to moderate severity (CC 20-60 ml / min);
  
• primary aldosteronism;
  
• vasorenal hypertension (bilateral renal artery stenosis or single kidney artery stenosis);
  
• other conditions accompanied by the activation of the renin-anginotensin-aldosterone system;
  
• chronic heart failure (CHF) (III-IV functional class according to NYHA classification);
  
• chronic forms of coronary heart disease;
  
• acute forms of coronary heart disease (acute myocardial infarction, including within one month after it; unstable angina);
  
• sinus node weakness syndrome;
  
• arterial hypotension;
  
• cerebrovascular diseases;
  
• liver failure of mild to moderate severity (less than 9 points on the child-Pugh scale);
  
• over 65 years of age;
  
• use in patients of the Negroid race.